Myelodysplastic Syndromes (MDS)
Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AML
To improve the tolerability of post-transplant maintenance and outcomes despite poor risk disease genetics, we conducted a phase 1 study of venetoclax venetoclax:
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial
Measurable residual disease (MRD) can predict relapse in patients with advanced myelodysplastic neoplasms (MDS) or acute myeloid leukemia
Updates in low/intermediate-risk MDS
Low- and intermediate-risk myelodysplastic syndromes myelodysplastic syndromes:
Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study
The COMMANDS trial established luspatercept as a first-line treatment for anemia anemia:
Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability
Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potential curative therapy for myelodysplastic syndrome (MDS), recommended in higher risk disease according to the International Prognostic Scoring System
Aplastic Anemia, MDS, PNH Virtual Support Group-Saturdays-2026 March
AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare and serious co
MDS Virtual Support Group - Evenings- 2025 March
AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with MDS. The group is hosted by AAMDSIF and will be monitored to ensure the privacy and safety of our participants.